Clinical Takeaway
In this pilot RCT of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that this cannabinoid combination did not improve objective sleep duration in the short term. High-density EEG allowed detailed assessment of sleep architecture, and next-day alertness was also monitored, providing a more complete picture of acute cannabinoid effects than most prior studies. These findings highlight that patient-reported benefits from cannabis sleep aids may not always align with objective polysomnographic outcomes, underscoring the need for larger controlled trials before clinical recommendations can be made.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution EEG characterization of how THC/CBD combination affects sleep architecture and vigilance in diagnosed insomnia patients, addressing a critical gap since cannabinoids are widely used clinically despite limited objective neurophysiological data. The 256-channel EEG methodology enables detection of subtle changes in sleep stage progression and cortical activity that standard polysomnography cannot capture, informing whether cannabinoid effects translate to genuine sleep consolidation or merely subjective improvement. These findings are essential for establishing evidence-based dosing guidelines and identifying which insomnia phenotypes may benefit from cannabinoid therapy versus those at risk for tolerance or next-day impairment.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 While this pilot study provides valuable objective neurophysiological data on cannabinoid effects in insomnia using high-density EEG, the small sample size of 20 participants and single-dose design significantly limit generalizability to clinical practice patterns, where patients typically use cannabis repeatedly over weeks or months. The specific THC/CBD ratio tested (10:20) may not reflect the diverse formulations patients actually access, and the study’s focus on acute effects tells us little about tolerance development, next-day cognitive or motor effects in real-world contexts, or how outcomes differ across age groups, comorbidities, or concurrent medications. Important confounders including baseline cannabis experience, expectancy effects, and circadian timing are not clearly addressed in the available abstract. Despite these limitations, this research usefully documents that cannabinoids do produce measurable EEG changes in people with insomnia, which can inform more rigorous follow-up trials; clinically, this suggests that if you do recommend cannabinoids for sleep, counseling